We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-7.28%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.53B
AUM Growth
-$382M
Cap. Flow
+$195M
Cap. Flow %
2.99%
Top 10 Hldgs %
59.37%
Holding
305
New
83
Increased
54
Reduced
76
Closed
50

Top Buys

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$108M
2
BUD icon
AB InBev
BUD
+$39.8M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$33.9M
4
CRL icon
Charles River Laboratories
CRL
+$32M
5
CL icon
Colgate-Palmolive
CL
+$27M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$93.3M
2
PFE icon
Pfizer
PFE
+$76.9M
3
JNJ icon
Johnson & Johnson
JNJ
+$53.7M
4
INCY icon
Incyte
INCY
+$46.6M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$45.7M

Sector Composition

Rank Sector Weight
1 Healthcare 34.38%
2 Consumer Staples 6.6%
3 Technology 4.23%
4 Consumer Discretionary 3.89%
5 Communication Services 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$1.92B 29.46%
4,500,000
+300,000
+7% +$133M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$1.15B 17.6%
6,500,000
+1,200,000
+23% +$225M
SUPN icon
3
Supernus Pharmaceuticals
SUPN
$2.68B
$140M 2.15%
5,092,000
+56,000
+1% +$1.7M
PTCT icon
4
PTC Therapeutics
PTCT
$6.37B
$138M 2.11%
6,150,000
+2,914,000
+90% +$108M
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.7B
$137M 2.1%
1,216,365
-433,635
-26% -$45.7M
ARGX icon
6
argenx
ARGX
$57.4B
$98.3M 1.51%
200,000
– –
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.16B
$82.3M 1.26%
3,324,000
+68,000
+2% +$1.8M
BIIB icon
8
Biogen
BIIB
$29.9B
$71.1M 1.09%
276,788
+20,788
+8% +$5.56M
ARGX icon
9
CALL
argenx
ARGX
$57.4B
$68.8M 1.05%
+140,000
New +$68.5M
CL icon
10
Colgate-Palmolive
CL
$72.6B
$68.4M 1.05%
962,000
+361,000
+60% +$27M
TVTX icon
11
Travere Therapeutics
TVTX
$5.33B
$67M 1.03%
7,500,000
+50,000
+0.7% +$706K
NVRO
12
DELISTED
NEVRO CORP.
NVRO
$66.4M 1.02%
3,456,000
+1,100,000
+47% +$23.5M
AMZN icon
13
Amazon
AMZN
$2.5T
$66.3M 1.02%
521,369
-2,631
-0.5% -$353K
XRAY icon
14
Dentsply Sirona
XRAY
$2.59B
$62.4M 0.96%
1,827,805
+27,805
+2% +$1.06M
REGN icon
15
Regeneron Pharmaceuticals
REGN
$68.8B
$61.7M 0.95%
74,998
-49,002
-40% -$38.5M
GOOGL icon
16
Alphabet (Google) Class A
GOOGL
$3.91T
$61.4M 0.94%
469,575
-78,425
-14% -$10.1M
UNH icon
17
UnitedHealth
UNH
$382B
$60.5M 0.93%
120,000
-30,000
-20% -$14.8M
INCY icon
18
Incyte
INCY
$23.5B
$59.8M 0.92%
1,036,000
-740,000
-42% -$46.6M
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$59.4M 0.91%
1,364,098
-2,613,902
-66% -$93.3M
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$58.7M 0.9%
4,612,000
+52,000
+1% +$717K
FRPT icon
21
Freshpet
FRPT
$2.83B
$53.7M 0.82%
814,729
-235,271
-22% -$16.9M
ALKS icon
22
Alkermes
ALKS
$8.82B
$53.1M 0.81%
1,896,775
-103,225
-5% -$3.03M
BHVN icon
23
Biohaven
BHVN
$2.16B
$53M 0.81%
2,036,000
+236,000
+13% +$4.91M
MDT icon
24
Medtronic
MDT
$107B
$52.6M 0.81%
671,407
-84,593
-11% -$7.08M
EXAS
25
DELISTED
Exact Sciences
EXAS
$48.5M 0.74%
711,520
+239,520
+51% +$20.3M
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Armistice Capital held 305 positions worth $6.53B, down 5.5% from $6.91B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Armistice Capital's Q3 2023 filing shows 83 new, 54 increased, 76 reduced and 50 closed positions. Its largest new stake was AB InBev: 703,000 shares worth $38.9M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $93.3M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 39% a quarter earlier, followed by Consumer Staples and Technology.

  • Armistice Capital's largest Q3 2023 buy was AB InBev: 703,000 shares worth $38.9M.
  • Armistice Capital added most to PTC Therapeutics in Q3 2023, an estimated $108M increase.
  • Armistice Capital's biggest Q3 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $93.3M.
  • Armistice Capital fully exited Pfizer in Q3 2023, selling an estimated $76.9M.
  • Armistice Capital's ten largest holdings make up 59% of its $6.53B portfolio in Q3 2023.
  • Armistice Capital opened 83 new positions and closed 50 in Q3 2023.
  • Armistice Capital's portfolio value fell 5.5% quarter-over-quarter to $6.53B.

Based on Armistice Capital's 13F filing for Q3 2023, filed 14 Nov 2023.